Evidence map›Paper›PMID 42859302›Full record

ArticleEndocrine2026

Dynamic transitions from prediabetes to diabetes and incident cardiovascular events in middle-aged and older chinese adults: a nationwide longitudinal study.

Shanshan Liang, Fei Ding, Xinyu Wang, Chuanmin Tao, Wei Gan

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shanshan Liang *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Fei Ding *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Xinyu WangDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Chuanmin TaoDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. Taocm@scu.edu.cn.
Wei GanDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. 2004ganwei@scu.edu.cn.

Funding

1.3.5 project for discipline of excellence, West China Hospital, Sichuan University 2025HXFH053
6 · The paper itself

Abstract

backgroundPrediabetes is a heterogeneous metabolic state that may revert to normoglycemia, persist, or progress to type 2 diabetes mellitus (T2DM). However, the cardiovascular implications of different prediabetes transition patterns and the ability to predict diabetes progression among middle-aged and older Chinese adults remain unclear. We aimed to characterize glycemic transitions, examine their associations with incident cardiovascular events, and develop prediction models for progression from prediabetes to T2DM.

methodsThis longitudinal cohort study used data from the China Health and Retirement Longitudinal Study. Glycemic status was defined according to American Diabetes Association criteria using fasting plasma glucose, HbA1c, self-reported diabetes, and medication use. Four-year glycemic transitions from Wave 1 to Wave 3 were assessed among 7,927 participants. Among participants with baseline prediabetes, multinomial logistic regression was used to identify factors associated with reversion to normal glucose tolerance or progression to T2DM. A Wave 3 landmark design was applied to examine subsequent incident heart disease and stroke in separate outcome-specific cohorts. Prediction models for 4-year T2DM progression were developed and internally validated using a stratified 70:30 training-test split; no external validation was performed.

resultsAmong 3,313 participants with baseline prediabetes, 696 (21.01%) reverted to normal glucose tolerance, 2,007 (60.58%) remained in prediabetes, and 610 (18.41%) progressed to T2DM over 4 years. Higher BMI, fasting glucose, HbA1c, dyslipidemia, smoking, and C-reactive protein, together with lower grip strength, were associated with higher odds of progression. Older age, male sex, higher fasting glucose, and higher HbA1c were associated with lower odds of reversion. Compared with stable normal glucose tolerance, prediabetes progression was associated with higher odds of incident heart disease (adjusted odds ratio [aOR], 1.53; 95% CI, 1.13-2.09), whereas the association with incident stroke was not statistically significant (aOR, 1.29; 95% CI, 0.90-1.87). Stable T2DM was associated with higher odds of both incident heart disease (aOR, 1.36; 95% CI, 1.04-1.79) and stroke (aOR, 1.44; 95% CI, 1.05-1.97). The full-variable logistic regression model achieved the highest discrimination for T2DM progression (AUC, 0.715; 95% CI, 0.674-0.754), modestly outperforming the clinical baseline model (AUC, 0.699; 95% CI, 0.656-0.739) and the evaluated tree-based models.

conclusionsPrediabetes showed dynamic 4-year transitions within the analytic cohort. Progression from prediabetes to T2DM was associated with higher subsequent odds of incident heart disease, whereas its adjusted association with incident stroke was not statistically significant. The full-variable logistic regression model showed moderate discrimination and only limited incremental improvement over the clinical baseline model; it should therefore be considered an exploratory risk-stratification tool requiring external validation rather than a clinically deployable prediction model.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Prediabetic StateAgedBlood GlucoseChinaDisease ProgressionEast Asian PeopleFemaleGlycated HemoglobinHumansIncidenceLongitudinal StudiesMaleMiddle AgedRisk FactorsBlood GlucoseGlycated HemoglobinCardiovascular eventsCHARLSGlycemic transitionLogistic regressionOlder adultsPrediabetesPrediction modelType 2 diabetes mellitus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.